Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Commodore Capital LP
Form 13F · Q2 2026

Commodore Capital LP

CIK 1831942Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.7B
Reported book value
33
Positions
12
Quarters on record
Top 50
Positions

Commodore Capital LP — holdings

Top 33 positions of 33, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1RLAY Relay Therapeutics Inc12.0M−29.4%$225M13.4%
2ELVN Enliven Therapeutics Inc3.3M+0.0%$166M9.9%
3ALKS Alkermes Plc3.0M−28.6%$157M9.4%
4COGT Cogent Biosciences Inc3.0M+5.6%$118M7.0%
5AMLX Amylyx Pharmaceuticals Inc5.7M+0.0%$101M6.0%
6DFTX Definium Therapeutics Inc2.0M+0.0%$94M5.6%
7SYRE Spyre Therapeutics Inc846,786−55.7%$75M4.5%
8ANRO Alto Neuroscience Inc2.7M+0.0%$72M4.3%
9TNGX Tango Therapeutics Inc2.2M—$70M4.2%
10EYPT Eyepoint Inc4.6M+62.8%$66M3.9%
11TYRA Tyra Biosciences Inc1.9M−24.2%$60M3.6%
12DMRA Damora Therapeutics Inc1.9M+0.0%$50M3.0%
13CLDX Celldex Therapeutics Inc New1.4M−49.9%$50M3.0%
14PHVS Pharvaris N V1.4M−25.7%$49M2.9%
15LBRX Lb Pharmaceuticals Inc1.5M+0.0%$49M2.9%
16ASMB Assembly Biosciences Inc1.4M+41.5%$39M2.3%
17EDIT Editas Medicine Inc8.9M—$29M1.7%
18KYMR Kymera Therapeutics Inc250,000−66.7%$29M1.7%
19CATX Perspective Therapeutics Inc6.3M+0.0%$22M1.3%
20IPSC Century Therapeutics Inc8.7M+0.0%$21M1.3%
21ZURA Zura Bio Ltd3.2M+0.0%$19M1.1%
22AVTX Avalo Therapeutics Inc1.0M+110.8%$19M1.1%
23INFLARX NV Inflarx Nv7.3M—$16M1.0%
24ANTX An2 Therapeutics Inc2.9M+25.7%$14M0.8%
25NUVALENT INC Nuvalent Inc100,000−88.0%$12M0.7%
26SABS Sab Biotherapeutics Inc2.9M−34.8%$11M0.7%
27IKT Inhibikase Therapeutics Inc5.4M+0.0%$11M0.7%
28RLMD Relmada Therapeutics Inc1.4M+124.8%$10M0.6%
29PEPG Pepgen Inc4.5M+0.0%$8M0.5%
30RACC Research Alliance Corp Iii500,000—$5M0.3%
31HLXC Helix Acquisition Corp Iii500,000+0.0%$5M0.3%
32LONA Leonabio Inc464,398+0.0%$4M0.3%
33VTGN Vistagen Therapeutics Inc2.8M—$630,2280.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.